A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers

Clinical Proteomics

Simon Fredriksson²  Mark S Baker⁴  Sadia Mahboob⁴  Sock-Hwee Tan⁴  Emma Rennel²  Shoba Ranganathan¹  David Cantor⁴  Edmond J Breen⁶  Seong Beom Ahn⁴  Md Golam Muktadir³  Alamgir Khan⁶  Edouard Nice⁵  Harish R Cheruku⁴  Gabriella Edfeldt²  Abidali Mohamedali¹ 

[1] Department of Chemistry and Biomolecular Sciences, Faculty of Science, Macquarie University, Sydney, AustraliaDepartment of Chemistry and Biomolecular Sciences, Faculty of Science, Macquarie University, Sydney, AustraliaDepartment of Chemistry and Biomolecular Sciences, Faculty of Science, Macquarie University, Sydney, Australia;Olink Bioscience, Uppsala, SwedenOlink Bioscience, Uppsala, SwedenOlink Bioscience, Uppsala, Sweden;School of Science and Health, University of Western Sydney, NSW, AustraliaSchool of Science and Health, University of Western Sydney, NSW, AustraliaSchool of Science and Health, University of Western Sydney, NSW, Australia;Australian School of Advanced Medicine, Faculty of Medicine and Human Sciences, Macquarie University, Sydney, AustraliaAustralian School of Advanced Medicine, Faculty of Medicine and Human Sciences, Macquarie University, Sydney, AustraliaAustralian School of Advanced Medicine, Faculty of Medicine and Human Sciences, Macquarie University, Sydney, Australia;Department of Biochemistry and Molecular Biology, Monash University, Melbourne, AustraliaDepartment of Biochemistry and Molecular Biology, Monash University, Melbourne, AustraliaDepartment of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia;Australian Proteome Analysis Facility, Macquarie University, Sydney, AustraliaAustralian Proteome Analysis Facility, Macquarie University, Sydney, AustraliaAustralian Proteome Analysis Facility, Macquarie University, Sydney, Australia

关键词: Multiplex immunoassay;    Plasma biomarker;    Colorectal cancer;   

DOI  :  10.1186/s12014-015-9081-x

来源: Humana Press Inc

【 摘 要 】

Abstract

Background

Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 μL) obtained from 75 patients with Dukes’ staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek® Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay.

Results

Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research. Proseek found that expression of Carcinoembryonic Antigen (CEA), IL-8 and prolactin are significantly correlated with CRC stage.

Conclusions

CEA, IL-8 and prolactin expression were found to identify between control (unaffected), non-malignant (Dukes’ A + B) and malignant (Dukes’ C + D) stages.

【 授权许可】

Unknown